Ethambutol Optic Neuropathy
Master ethambutol optic neuropathy for NBEO and OKAP: recognize dyschromatopsia, cecocentral scotomas, risk factors and urgent management.
Ethambutol toxicity most classically produces which visual field abnormality?
Ethambutol Optic Neuropathy in 30 Seconds
Ethambutol optic neuropathy is a dose- and duration-dependent bilateral toxic optic neuropathy that preferentially affects the papillomacular bundle. Early recognition matters because prompt drug cessation may limit damage, although visual recovery can be incomplete.
Clinical Features
- Symptoms: painless, progressive, bilateral central vision loss. Exam relevance: think toxic optic neuropathy.
- Color vision: dyschromatopsia, often red-green but occasionally blue-yellow, may occur early. Exam relevance: test color vision in exposed patients.
- Field defect: central or cecocentral scotoma from papillomacular bundle involvement. Exam relevance: this localizes the injury.
- Onset: usually follows months of therapy and depends on dose and duration. Exam relevance: review medication timing.
- Optic disc: often normal early, later showing temporal pallor. OCT may show ganglion cell layer thinning before obvious pallor. Exam relevance: a normal fundus does not exclude toxicity.
Risk Factors and Mechanism
- Dose: risk rises above 15 mg/kg/day and with longer treatment. Exam relevance: higher dose increases suspicion.
- Renal impairment: reduced clearance increases toxicity risk. Exam relevance: ask about kidney disease.
- Proposed mechanism: the exact mechanism is incompletely understood but may involve mitochondrial dysfunction related to zinc and copper chelation. Exam relevance: explains papillomacular vulnerability.
- Predisposition: mitochondrial and nutritional factors may contribute. Exam relevance: susceptibility varies between patients.
- Monitoring: check color vision, acuity and fields at baseline and periodically, with closer monitoring at higher doses or longer duration. Exam relevance: screening supports early detection.
4 Facts Exams Always Ask
- Painless bilateral central vision loss with red-green dyschromatopsia is the classic presentation.
- Papillomacular bundle damage produces a central or cecocentral scotoma.
- Risk increases above 15 mg/kg/day, with longer use and with renal impairment.
- Management is prompt ethambutol discontinuation. Recovery may occur but can be incomplete.
The Classic Trap
The main board trap is missing the medication history and attributing gradual bilateral vision loss with dyschromatopsia to another optic neuropathy. A normal optic disc early in the disease does not exclude ethambutol toxicity. Red-green color vision loss with a cecocentral scotoma in a patient receiving antituberculous therapy strongly points to ethambutol. Unlike nutritional optic neuropathy, there is a clear medication exposure.
Clinical Pearl
Ethambutol causes a toxic optic neuropathy with early red-green dyschromatopsia and a cecocentral scotoma, and the disc is often normal early. Coordinate prompt discontinuation with the prescribing physician. Recovery is possible but may be incomplete, so baseline and periodic screening are key. MRI is usually normal and mainly excludes other causes of bilateral optic neuropathy.
Checkpoint 1
Which finding is often an early sign of ethambutol optic neuropathy?
Checkpoint 2
Which factor most increases the risk of ethambutol optic neuropathy?
A patient receiving antituberculous therapy including ethambutol reports several months of gradual, painless bilateral central blur. Color testing is impaired and the fundus appears relatively normal. Visual fields show bilateral cecocentral defects. What is the most likely diagnosis?
A patient on antituberculous therapy including ethambutol has several months of painless bilateral central vision loss, impaired color vision, bilateral cecocentral scotomas and a relatively normal fundus. What is the most likely diagnosis?
Sources & Publisher Info
References
- American Academy of Ophthalmology. BCSC Section 5: Neuro-Ophthalmology.
- Miller NR, Newman NJ, Biousse V, Kerrison JB. Walsh and Hoyt Clinical Neuro-Ophthalmology.
- American Academy of Ophthalmology. EyeWiki: Toxic Optic Neuropathy.
More Pharmacology topics
Ready for the real thing?
Practice thousands of eye-care questions free on OcuQuiz. Earn points, build streaks and battle colleagues.
Practice Pharmacology →